Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jaguar Health, Inc.
Report date February 21, 2020 · Filed February 27, 2020
Section 16 reporting ended · disclosed 2020-02-27. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2019 Filed Jul 26, 2019 20:54 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 121,573 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001104659-19-042089 · a4.xml · derivative · entry 1 JOHNSON JEFFERY C. · CIK 0001735383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,573 Underlying: Common Stock · 121,573 shares Expires 2022-07-24 F1 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019. F3 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with one month of options, or 3,377 options, vested as of the grant date based on the reporting person's number of years of service on the issuer's board of directors, such that the grant is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| June 01, 2018 Filed Jun 7, 2018 01:38 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 104,860 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001104659-18-038715 · a4.xml · derivative · entry 1 JOHNSON JEFFERY C. · CIK 0001735383 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,860 Underlying: Common Stock · 104,860 shares Expires 2028-04-12 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan F2 · security: All share numbers and the exercise price reflect the 1-for-15 reverse stock split effected on June 1, 2018. F3 · date: The option grant was approved by the Issuer's board of directors on April 12, 2018, subject to the stockholders approving and effecting a reverse stock split. The Issuer's shareholders approved the reverse stock split on May 18, 2018 and effected such stock split on June 1, 2018. F4 · derivative.exercise_date: Vests in equal monthly installments, beginning on May 1, 2018, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.